Repligen's $1. 5 Billion Bet on Cell Therapy's Bright Future The pharmaceutical industry is abuzz with a new trend: the acquisition of companies specializing in cell therapy tools.
The latest deal making headlines is Repligen Corp's planned purchase of BioLife Solutions for a staggering $1. 5 billion, a move that has significant implications for the sector.
Repligen's bid to expand its presence in the fast growing cell therapy market has been facilitated by Danaher, which signaled a recovery in demand for bioprocessing products on Tuesday.